Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philipp Erben

Showing results (91-100 of 127) with videos related to

Pageof 13
Sort By:
Urologia Internationalis|December 20, 2016
ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situJohannes Breyer, Wolfgang Otto, Ralph M Wirtz, et al.
Haematologica|January 29, 2010
Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysisPhilipp Erben, Darko Gosenca, Martin C Müller, et al.
International Journal of Molecular Sciences|November 2, 2018
mRNA-Expression of <i>KRT5</i> and <i>KRT20</i> Defines Distinct Prognostic Subgroups of Muscle-Invasive Urothelial Bladder Cancer Correlating with Histological VariantsMarkus Eckstein, Ralph Markus Wirtz, Matthias Gross-Weege, et al.
Urologia Internationalis|January 21, 2024
An Empirical Survey on the Adaption of Neoadjuvant Chemotherapy in Bladder CancerMoritz J Reike, Alina Reicherz, Karl H Tully, et al.
Urologic Oncology|June 17, 2021
High IL-22RA1 gene expression is associated with poor outcome in muscle invasive bladder cancerKatja Nitschke, Thomas S Worst, Sophie Madeleine von Rhade, et al.
Cancer Management and Research|August 27, 2021
The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder CancerDanijel Sikic, Helge Taubert, Johannes Breyer, et al.
Blood|January 13, 2011
Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like diseaseChristian Elling, Philipp Erben, Christoph Walz, et al.
Genes, Chromosomes & Cancer|April 29, 2014
Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasmsDarko Gosenca, Beate Kellert, Georgia Metzgeroth, et al.
Iscience|August 9, 2023
Reinvestigating the clinical relevance of the m<sup>6</sup>A writer METTL3 in urothelial carcinoma of the bladderJonas Koch, Manuel Neuberger, Martina Schmidt-Dengler, et al.
Urologic Oncology|April 15, 2026
Concordance and prognostic value of antibody drug conjugate and checkpoint inhibition targets in matched bladder cancer specimens from transurethral resection of the bladder, radical cystectomy and lymphadenectomyDaniel Uysal, Bruno Reible, Lukas Wildner, et al.
Pageof 13

Showing results (91-100 of 127) with videos related to

Sort By:
Pageof 13
Urologia Internationalis|December 20, 2016
ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situJohannes Breyer, Wolfgang Otto, Ralph M Wirtz, et al.
Haematologica|January 29, 2010
Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysisPhilipp Erben, Darko Gosenca, Martin C Müller, et al.
International Journal of Molecular Sciences|November 2, 2018
mRNA-Expression of <i>KRT5</i> and <i>KRT20</i> Defines Distinct Prognostic Subgroups of Muscle-Invasive Urothelial Bladder Cancer Correlating with Histological VariantsMarkus Eckstein, Ralph Markus Wirtz, Matthias Gross-Weege, et al.
Urologia Internationalis|January 21, 2024
An Empirical Survey on the Adaption of Neoadjuvant Chemotherapy in Bladder CancerMoritz J Reike, Alina Reicherz, Karl H Tully, et al.
Urologic Oncology|June 17, 2021
High IL-22RA1 gene expression is associated with poor outcome in muscle invasive bladder cancerKatja Nitschke, Thomas S Worst, Sophie Madeleine von Rhade, et al.
Cancer Management and Research|August 27, 2021
The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder CancerDanijel Sikic, Helge Taubert, Johannes Breyer, et al.
Blood|January 13, 2011
Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like diseaseChristian Elling, Philipp Erben, Christoph Walz, et al.
Genes, Chromosomes & Cancer|April 29, 2014
Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasmsDarko Gosenca, Beate Kellert, Georgia Metzgeroth, et al.
Iscience|August 9, 2023
Reinvestigating the clinical relevance of the m<sup>6</sup>A writer METTL3 in urothelial carcinoma of the bladderJonas Koch, Manuel Neuberger, Martina Schmidt-Dengler, et al.
Urologic Oncology|April 15, 2026
Concordance and prognostic value of antibody drug conjugate and checkpoint inhibition targets in matched bladder cancer specimens from transurethral resection of the bladder, radical cystectomy and lymphadenectomyDaniel Uysal, Bruno Reible, Lukas Wildner, et al.
Pageof 13